17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown. In this pilot study we determined the effects of empagliflozin 10 mg/d for 4 weeks on peak oxygen consumption (VO2 ) in 15 patients with T2DM and HFrEF. As an exploratory analysis, we assessed whether there was an interaction of the effects of empagliflozin on peak VO2 of loop diuretics. Empagliflozin reduced body weight (-1.7 kg; P = .031), but did not change peak VO2 (from 14.5 mL kg-1 min-1 [12.6-17.8] to 15.8 [12.5-17.4] mL kg-1 min-1 ; P = .95). However, patients using loop diuretics (N = 9) demonstrated an improvement, whereas those without loop diuretics (N = 6) experienced a decrease in peak VO2 (+0.9 [0.1-1.4] vs -0.9 [-2.1 to -0.3] mL kg-1 min-1 ; P = .001), and peak VO2 changes correlated with the baseline daily dose of diuretics (R = +0.83; P < .001). Empagliflozin did not improve peak VO2 in patients with T2DM and HFrEF. However, as a result of exploratory analysis, patients concomitantly treated with loop diuretics experienced a significant improvement in peak VO2 .

          Related collections

          Author and article information

          Journal
          Diabetes Obes Metab
          Diabetes, obesity & metabolism
          Wiley
          1463-1326
          1462-8902
          August 2018
          : 20
          : 8
          Affiliations
          [1 ] Department of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
          [2 ] Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
          [3 ] Kinesiology and Health Science, College of Humanities and Sciences, Virginia Commonwealth University, Richmond, Virginia.
          [4 ] Department of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University, Richmond, Virginia.
          [5 ] Division of Cardiovascular Medicine and Department of Pharmacy Service, Brigham and Women's Hospital, Boston, Massachusetts.
          Article
          NIHMS956018
          10.1111/dom.13309
          6043379
          29603546
          9983a443-e636-405f-b0c6-87d99823aab3
          History

          empagliflozin,SGLT2 inhibitors,cardiorespiratory fitness,diuretics,heart failure

          Comments

          Comment on this article